



To: Carter BloodCare Customers
From: Hospital Relations Department
Date: June 11, 2021
Re: Zika Virus Testing Discontinuation

When Zika Virus (ZIKV) testing was mandated in 2016, Carter BloodCare applied a service surcharge to cover the fee of what was then an investigational assay. The FDA then approved the assay, and beginning January 1, 2019, an \$8 fee increase was applied to all red cell and apheresis platelet components.

On May 12, 2021, the FDA's July 2018 ZIKV Testing Guidance was withdrawn because the agency determined that testing for ZIKV, or pathogen reduction as an alternative to testing for ZIKV, is not necessary because ZIKV is no longer a Relevant Transfusion-Transmitted Infection (RTTI).

Effective June 15, 2021, all red cell and apheresis platelet components will be decreased by the previously assessed \$8.00 ZIKV testing fee.

Please contact hospitalrelations@carterbloodcare.org with any questions or concerns.